Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Forte Biosciences (FBRX) Research & Development (2016 - 2020)

Forte Biosciences (FBRX) has disclosed Research & Development for 5 consecutive years, with $3.0 million as the latest value for Q4 2020.

  • Quarterly Research & Development rose 161.23% to $3.0 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $10.0 million through Dec 2020, down 29.82% year-over-year, with the annual reading at $57.6 million for FY2025, 178.3% up from the prior year.
  • Research & Development for Q4 2020 was $3.0 million at Forte Biosciences, down from $3.7 million in the prior quarter.
  • The five-year high for Research & Development was $15.6 million in Q4 2018, with the low at $310000.0 in Q2 2019.
  • Average Research & Development over 5 years is $6.6 million, with a median of $6.6 million recorded in 2017.
  • The sharpest move saw Research & Development crashed 97.57% in 2019, then surged 944.76% in 2020.
  • Over 5 years, Research & Development stood at $6.6 million in 2016, then rose by 25.04% to $8.3 million in 2017, then surged by 88.32% to $15.6 million in 2018, then plummeted by 92.59% to $1.2 million in 2019, then surged by 161.23% to $3.0 million in 2020.
  • According to Business Quant data, Research & Development over the past three periods came in at $3.0 million, $3.7 million, and $1.9 million for Q4 2020, Q3 2020, and Q2 2020 respectively.